News Center
The list of the top 100 Chinese pharmaceutical companies for 2022 has been released, with Livzon Group ranking 21st and being awarded "2023 China's Most Investment-Value Pharmaceutical Company".
Release time:
2023-11-20
From November 17 to 19, the 40th National Pharmaceutical Industry Information Conference, hosted by the China Pharmaceutical Industry Information Center, was held in Beijing. At the conference, the "2022 Annual List of China's Top 100 Pharmaceutical Companies" was released, with Livzon Pharmaceutical Group ranking 21st and being awarded the title of "2023 Most Investment-Value Enterprise in China's Pharmaceutical Industry."
The conference was jointly organized by the Ministry of Industry and Information Technology, the People's Government of Beijing Municipality, the National Health Commission, the State-owned Assets Supervision and Administration Commission of the State Council, the National Administration of Traditional Chinese Medicine, and the National Medical Products Administration. The theme of the conference was "Gathering Development Forces to Build a Solid Foundation for Health," focusing on the pharmaceutical industry, strengthening dialogue and communication, and creating an industrial ecosystem. It comprehensively showcased the outstanding achievements and comprehensive capabilities of China's pharmaceutical industry in areas such as chemical drugs, traditional Chinese medicine, biological drugs, and medical device manufacturing, providing a platform for communication and cooperation among various industry stakeholders.
The list of China's top 100 pharmaceutical companies is currently an authoritative industry ranking in the country, with selected companies being outstanding representatives of China's pharmaceutical industry. Livzon Pharmaceutical Group ranked 21st on the list, reflecting the company's overall strength, innovation capability, and social influence.
To deeply explore the transformation context of the pharmaceutical industry, the China Pharmaceutical Industry Information Center formed an expert evaluation group, relying on resources such as the new drug research and development monitoring database, the comprehensive drug evaluation system database, the hospital market analysis system, and the China drug retail market database. The evaluation was conducted from two levels: drugs and companies. At the drug level, it examined innovation dimensions, strategic dimensions, maturity dimensions, development dimensions, competitive dimensions, and status dimensions; at the company level, it examined characteristic dimensions, leading dimensions, scale dimensions, stability dimensions, overlap dimensions, and growth dimensions, establishing scientific evaluation criteria to select the annual "Most Investment-Value Enterprise in China's Pharmaceutical Industry." Livzon Pharmaceutical Group was awarded the title of "2023 Most Investment-Value Enterprise in China's Pharmaceutical Industry," reflecting widespread recognition from all sectors of society for Livzon's steady development.
In recent years, Livzon Pharmaceutical Group has taken research and development innovation as the cornerstone of sustainable development, adhering to the development driven by innovative drugs and high-barrier complex formulations. The company continues to focus on new molecules and cutting-edge technologies in the global new drug research and development field, based on clinical value and differentiated forward-looking layout of innovative drugs and high-barrier complex formulations, focusing on areas such as the digestive tract, assisted reproduction, mental health, and tumor immunity, forming a complete product cluster and a differentiated product pipeline covering the entire research and development cycle.
Livzon Pharmaceutical Group has always been patient clinical demand-oriented, accelerating the improvement of research and development efficiency through digital and intelligent technology models, further strengthening its leading advantage in innovative drugs and high-barrier complex formulation platforms, and comprehensively enhancing its sustainable development capabilities. At the same time, it actively responds to national policy calls, continuously shouldering the responsibilities of a pharmaceutical enterprise, and contributing more Livzon strength to a healthy China.
Related Information